Juno Therapeutics, Inc. (NASDAQ:JUNO) was less active in the last trading session as around 2.73 million shares exchanged hands on Wall Street, representing a decrease from its normal capacity of 3.05 million shares. A -6.85% change after the initial price of $60.88, sent the closing price to $56.99.Juno Therapeutics, Inc. (JUNO) Analyst Opinion
Juno Therapeutics, Inc. has a consensus outperform rating from 14 Wall Street analysts, and the number of shares currently sold short amount to at least 9.82% of shares outstanding. The stock spiked 24.65% last month and is up 202.33 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover JUNO having a buy-equivalent rating. Analysts have placed a $55.54 price target on Juno Therapeutics, Inc., suggesting a -2.54% decline from recent close. It’s currently trading about -10.18% below its 52-week high.
Juno Therapeutics, Inc. (JUNO) surprised the stock market in its last reported earnings when it earned -$0.73 a piece versus the consensus-estimated -$0.86. Its revenue totaled $16.2 million down -23.84% from the previous quarter.Juno Therapeutics, Inc. (NASDAQ:JUNO) Intraday View
This stock (JUNO) is ahead of its 52-week low with 225.29%. Its last month’s stock price volatility remained 5.2% which for the week stands at 6.35%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.57% and stays 16.93% away from its 50 days moving average. Over the last five days, shares have faced -3.5% losses and now is up 76.37% since hitting its 200-day moving average of $36.43. Juno Therapeutics, Inc. (JUNO) has made its way to a 12-month gain of 157.64%.
Turning to ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), its shares were trading at $70.31 a gain of $3.63, on the trading floor. The stock, after opening at $67.39, touched a high of $71.8 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. ANI Pharmaceuticals, Inc. has 2 buy ratings, 1 holds and 0 sells even after the stock tumbled -5.88% from its high of $74.70 to a $695.37 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1.67 to 1.67 during a month. Analysts set a 12-month price target of $66.33 a share. The target implies a -5.66% decrease from where the shares are currently trading. Also, the current price highlights a discount of -1.86% to analysts’ high consensus price target.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Intraday Trading
The counter witnessed a trading volume of 0.66 million shares versus an average volume of 0.13 million shares during last trading session. Its last month’s stock price volatility remained 7.99% which for the week approaches 5.05%. The lowest price the stock reached in the last trading day was $67.1 and compares with the $42.23 52-week low. The stock recovered 66.49% since its low point and has performed 15.98% year-to-date.